Retrieved from Gonzalez-Rellan, M
Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model
In clinical trials reported on the drugs label, 15.8% of patients taking the 5 mg dose and 20.3% of patients taking the 1 mg dose reported nausea
At 80 weeks, results showed that all three doses of retatrutide met the primary and key secondary end points for obesity, with clinically meaningful weight loss in all three groups
GLP-1s (glucagon-like peptide-1 receptor agonists) mimic a natural gut hormone that helps regulate: Appetite and satiety Blood sugar control Insulin release Digestive speed and energy At these low doses , you still gain the benefits, reduced cravings, steadier energy, and improved mood, without the intensity or side effects that can accompany higher doses
A preprint study (meaning it has not yet been peer-reviewed for publication in a medical journal) found that women taking semaglutide (Wegovy) or tirzepatide (Zepbound) had a 2.5-fold higher rate of nausea and vomiting compared with men
